GENE ONLINE|News &
FDA Approves PADCEV and Keytruda Perioperative Therapy: A Game-Changer for Cisplatin-Ineligible Bladder Cancer Patients
The U.S. FDA has granted a landmark approval for a new perioperative treatment strategy for adults with muscle-invasive bladder cancer (MIBC) who are ineligible for cisplatin-based chemotherapy. The regimen combines the antibody–drug conjugate PADCEV® (enfortumab vedotin-ejfv) with the immune checkpoint inhibitor Keytruda® (pembrolizumab), or its new subcutaneous formulation Keytruda Qlex™. This is currently the only FDA-approved therapy that can be used both before and after surgery and has been shown to significantly improve survival outcomes compared with surgery alone in this high-risk population. For patients who previously had limited systemic options, this represents a new standard of care.
MIBC is an aggressive form of bladder cancer, characterized by tumor invasion into the muscular wall of the bladder and a high risk of spread to lymph nodes and distant organs. Traditionally, cisplatin-based chemotherapy given before radical cystectomy has been the standard approach to improve long-term outcomes. However, many patients—often older individuals or those with kidney impairment, hearing loss, neuropathy, or multiple comorbidities—cannot safely receive cisplatin. These “cisplatin-ineligible” patients have long faced a therapeutic gap, relying mainly on surgery alone and then observation, despite substantial risks of recurrence and metastasis.
The new regimen targets this exact group. It is used as perioperative therapy, meaning it surrounds the surgical procedure. Before surgery, PADCEV plus Keytruda or Keytruda Qlex is given as neoadjuvant treatment to shrink the tumor and tackle microscopic disease that may already be circulating in the body. After radical cystectomy, the same combination continues as adjuvant therapy to further reduce the risk of relapse and disease progression. Instead of viewing surgery as the sole weapon, this approach treats bladder cancer as a systemic disease from the start, integrating modern pharmacologic therapy with surgical management.
How PADCEV and Keytruda Work Together to Improve Outcomes
The scientific basis for this approval largely comes from the phase 3 EV-303 trial. In this study, perioperative treatment with PADCEV + Keytruda was compared with surgery alone in cisplatin-ineligible MIBC patients. The combination significantly lowered the risk of disease recurrence, progression, or death by about 60% versus surgery alone. Such a marked improvement in event-free outcomes is considered practice-changing and has led experts to describe the regimen as a “true game-changer” for this underserved group.
Mechanistically, PADCEV and Keytruda attack cancer from two complementary directions. PADCEV is an antibody–drug conjugate targeting Nectin-4, a protein highly expressed on bladder cancer cells but limited in most normal tissues. By binding to Nectin-4, it delivers a potent cytotoxic payload directly into tumor cells, causing targeted cell death and releasing tumor antigens. Keytruda, a PD-1 inhibitor, removes inhibitory signals on T cells, allowing the immune system to recognize and destroy cancer cells more effectively. When combined, PADCEV’s tumor-killing action and antigen release can enhance the immune visibility of the cancer, while Keytruda amplifies the body’s ability to attack those newly exposed targets. This dual mechanism is believed to underpin the powerful clinical effects observed.
A notable aspect of the approval is the inclusion of Keytruda Qlex, a subcutaneous formulation of pembrolizumab. Unlike the traditional intravenous infusion, Qlex can be administered via injection under the skin in a shorter time frame. For patients, this can mean less time in the clinic and a more convenient treatment experience. For hospitals and infusion centers, it may improve chair turnover and reduce resource burden, allowing staff and infrastructure to be used more efficiently while maintaining therapeutic efficacy.
The approval also reflects a growing trend toward multi-company and multi-mechanism collaboration in oncology. PADCEV was co-developed by Seagen and Astellas and is now part of Pfizer’s oncology portfolio following its acquisition of Seagen. Keytruda is Merck/MSD’s flagship immunotherapy. Their strategic alliance in clinical development and commercialization highlights how modern cancer treatment is increasingly built on cross-company partnerships and rational drug combinations, rather than single-agent strategies confined to one manufacturer’s pipeline.
Transforming Bladder Cancer Care: From Surgery Alone to Perioperative Combination Therapy
Clinically, this change will require updates to treatment pathways and closer collaboration among urologists, medical oncologists, radiologists, and pathologists. Multidisciplinary teams will need to evaluate cisplatin eligibility early, discuss perioperative systemic therapy at the time of diagnosis, and coordinate timing between systemic treatment and surgery. Hospitals will also need to revise guidelines and patient education materials to explain the longer but more comprehensive treatment journey—one that may span several months, but offers better prospects for disease-free and overall survival.
For patients and families, the most meaningful impact is the shift from a limited, surgery-only strategy to a robust, evidence-based option tailored to those who cannot receive cisplatin. Instead of passively hoping surgery alone will be enough, they can now actively consider perioperative PADCEV + Keytruda / Keytruda Qlex, weighing potential side effects and logistical demands against significantly improved outcomes. Emotionally, it restores a sense of agency and hope to a group that often felt left out of advances in cancer care.
Overall, this FDA decision not only fills a long-standing treatment gap but also signals that bladder cancer has firmly entered a new era of “targeted drug + immunotherapy” dual-attack strategies, especially for high-risk patients who need better answers.
Related posts:
AACR Conference – Major Highlights of Immunotherapy Clinical Trials
Bavencio Bags FDA Approval as First-line Maintenance Treatment for Urothelial Carcinoma
Merck’s Keytruda Bags FDA Approval for Early Kidney Cancer in Adjuvant Setting
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
